Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US
STOCKHOLM, SWEDEN, May 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has reached a new milestone with 10,000 patients treated with the innovative nanosynthetic bone graft OssDsign Catalyst on the US market.
OssDsign Catalyst is a nanosynthetic bone graft that demonstrates rapid and robust bone formation, even in poorly vascularized environments. Launched in the US in August 2021, OssDsign Catalyst has since achieved significant success in the American orthobiologics market.
“It is clear that OssDsign Catalyst has solidified its position in the important US market for orthobiological products. The use of the product has doubled since May of last year, when 5,000 patients were reported to have been treated with the product, which is the result of accelerating demand from American surgeons and hospitals,” says Viktor Drvota, CEO of Karolinska Development.
Karolinska Development's ownership in OssDsign amounts to 3 %.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: 2, e-mail:
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail:
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit .
Attachment
